Chemotherapy-induced peripheral neuropathy (CIPN) remains one of the most common and challenging complications of cancer treatment. While significant progress has been made in understanding the condition, measuring treatment success and developing effective therapies continue to present important challenges.

In this episode, Professor Susanna Park and Dr. Paola Alberti welcome Associate Professor Jennifer Gewandter, an internationally recognized expert in pain research, peripheral neuropathy, and clinical trial methodology. Together they explore how researchers evaluate CIPN and examine how clinical trials can better reflect what matters most to patients.

References: 

  • Ventzel L, Bruna J, Cavaletti G. Concerns About Conclusions of the POLAR Trial. JAMA Oncol. 2025 Sep 1;11(9):1097-1098. doi: 10.1001/jamaoncol.2025.2355. PMID: 40742580.
  • https://pnsociety.com/wp-content/uploads/Saab_2025_personalized-outcomes.pdf
  • https://pnsociety.com/wp-content/uploads/Gewandter_CIPN-trial-design_Neurology.pdf

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Peripheral Nerve Society (PNS). Innehållet i podden är skapat av Peripheral Nerve Society (PNS) och inte av, eller tillsammans med, Poddtoppen.